BIM expression in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia.

被引：0
|
作者：
Cardona, Andres F.
Karachallou, Niki
Drozdowskyj, Ana
Gimenez Capitan, Ana
Angel Molina-Vila, Miguel
Arrieta, Oscar
Carranza, Hernan
Vargas, Carlos A.
Otero, Jorge M.
Rosell, Rafael
机构：
[1] Fdn Santa Fe Bogota, Bogota, Colombia
[2] Pangaea Biotech, Lab Translat Oncol, Barcelona, Spain
[3] Pivotal, Madrid, Spain
[4] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico
[5] Fdn Santa Fe Bogota, Clin & Traslat Oncol Grp, Bogota, Colombia
[6] Hosp Badalona Germans Trias & Pujol, USP Inst Univ Dexeus, Canc Therapeut Innovat Grp, Catalan Inst Oncol,Pangaea Biotech, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19098
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Mari Tone
    Kota Iwahori
    Takayuki Shiroyama
    Shinji Futami
    Yujiro Naito
    Kiyoharu Fukushima
    Kotaro Miyake
    Shohei Koyama
    Haruhiko Hirata
    Izumi Nagatomo
    Hisashi Wada
    Yoshito Takeda
    Atsushi Kumanogoh
    Scientific Reports, 13
  • [22] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [24] Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
    Niki Karachaliou
    Jordi Codony-Servat
    Cristina Teixidó
    Sara Pilotto
    Ana Drozdowskyj
    Carles Codony-Servat
    Ana Giménez-Capitán
    Miguel Angel Molina-Vila
    Jordi Bertrán-Alamillo
    Radj Gervais
    Bartomeu Massuti
    Teresa Morán
    Margarita Majem
    Enriqueta Felip
    Enric Carcereny
    Rosario García-Campelo
    Santiago Viteri
    María González-Cao
    Daniela Morales-Espinosa
    Alberto Verlicchi
    Elisabetta Crisetti
    Imane Chaib
    Mariacarmela Santarpia
    José Luis Ramírez
    Joaquim Bosch-Barrera
    Andrés Felipe Cardona
    Filippo de Marinis
    Guillermo López-Vivanco
    José Miguel Sánchez
    Alain Vergnenegre
    José Javier Sánchez Hernández
    Isabella Sperduti
    Emilio Bria
    Rafael Rosell
    Scientific Reports, 13
  • [25] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [26] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
    Ramotar, Matthew
    Barnes, Sierra
    Doherty, Mark
    Shultz, David Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [28] Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Cho, B. C.
    Lee, S. -H.
    Han, J. -Y.
    Cho, E. K.
    Lee, J. -S.
    Lee, K. H.
    Curtin, J. C.
    Gao, G.
    Xie, J.
    Schnepp, R. W.
    Bauml, J. M.
    Knoblauch, R. E.
    Thayu, M.
    Kim, D. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S126 - S126
  • [29] Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
    Lee, Dae Ho
    PHARMACOLOGY & THERAPEUTICS, 2017, 174 : 1 - 21
  • [30] Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
    Ma, Y.
    Zhao, H.
    Zhao, Y.
    Cheng, Y.
    Cui, J.
    Liu, G.
    Xiong, D.
    Zhang, J.
    Xu, L.
    Yu, J.
    Men, L.
    Liang, E.
    Yang, D.
    Zhang, L.
    Zhai, Y.
    ANNALS OF ONCOLOGY, 2023, 34
12345